Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that accounts for about 60% of all diagnosed cases of dementia worldwide. Although there are currently several drugs marketed for its treatment, none are capable of slowing down or stopping the progression of AD. The role of the b...

Descripción completa

Detalles Bibliográficos
Autores: Del Amo Albiol, Laura, Cano Fernández, Amanda, Ettcheto Arriola, Miren, Souto, Eliana B., Espina García, Marta, Camins Espuny, Antoni, García, Maria Luisa, Sánchez-López, E. (Elena)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/177480
Acceso en línea:https://hdl.handle.net/2445/177480
Access Level:acceso abierto
Palabra clave:Malaltia d'Alzheimer
Nanopartícules
Farmacologia
Alzheimer's disease
Nanoparticles
Pharmacology
id ES_c219deef2494be5347c91c15cb74c84c
oai_identifier_str oai:diposit.ub.edu:2445/177480
network_acronym_str ES
network_name_str España
repository_id_str
spelling Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's diseaseDel Amo Albiol, LauraCano Fernández, AmandaEttcheto Arriola, MirenSouto, Eliana B.Espina García, MartaCamins Espuny, AntoniGarcía, Maria LuisaSánchez-López, E. (Elena)Malaltia d'AlzheimerNanopartículesFarmacologiaAlzheimer's diseaseNanoparticlesPharmacologyAlzheimer's disease (AD) is a chronic neurodegenerative disorder that accounts for about 60% of all diagnosed cases of dementia worldwide. Although there are currently several drugs marketed for its treatment, none are capable of slowing down or stopping the progression of AD. The role of the blood-brain barrier (BBB) plays a key role in the design of a successful treatment for this neurodegenerative disease. Nanosized particles have been proposed as suitable drug delivery systems to overcome BBB with the purpose of increasing bioavailability of drugs in the brain. Biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NPs) have been particularly regarded as promising drug delivery systems as they can be surface-tailored with functionalized molecules for site-specific targeting. In this review, a thorough discussion about the most recent functionalization strategies based on PLGA-NPs for AD and their mechanisms of action is provided, together with a description of AD pathogenesis and the role of the BBB in brain targeting. Keywords: functionalized PLGA nanoparticles; brain delivery; blood-brain barrier; Alzheimer's diseaseMDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/177480Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/app11094305Applied Sciences, 2021https://doi.org/10.3390/app11094305cc-by (c) Del Amo Albiol, Laura et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1774802026-05-27T06:46:51Z
dc.title.none.fl_str_mv Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
title Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
spellingShingle Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
Del Amo Albiol, Laura
Malaltia d'Alzheimer
Nanopartícules
Farmacologia
Alzheimer's disease
Nanoparticles
Pharmacology
title_short Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
title_full Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
title_fullStr Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
title_full_unstemmed Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
title_sort Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer's disease
dc.creator.none.fl_str_mv Del Amo Albiol, Laura
Cano Fernández, Amanda
Ettcheto Arriola, Miren
Souto, Eliana B.
Espina García, Marta
Camins Espuny, Antoni
García, Maria Luisa
Sánchez-López, E. (Elena)
author Del Amo Albiol, Laura
author_facet Del Amo Albiol, Laura
Cano Fernández, Amanda
Ettcheto Arriola, Miren
Souto, Eliana B.
Espina García, Marta
Camins Espuny, Antoni
García, Maria Luisa
Sánchez-López, E. (Elena)
author_role author
author2 Cano Fernández, Amanda
Ettcheto Arriola, Miren
Souto, Eliana B.
Espina García, Marta
Camins Espuny, Antoni
García, Maria Luisa
Sánchez-López, E. (Elena)
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malaltia d'Alzheimer
Nanopartícules
Farmacologia
Alzheimer's disease
Nanoparticles
Pharmacology
topic Malaltia d'Alzheimer
Nanopartícules
Farmacologia
Alzheimer's disease
Nanoparticles
Pharmacology
description Alzheimer's disease (AD) is a chronic neurodegenerative disorder that accounts for about 60% of all diagnosed cases of dementia worldwide. Although there are currently several drugs marketed for its treatment, none are capable of slowing down or stopping the progression of AD. The role of the blood-brain barrier (BBB) plays a key role in the design of a successful treatment for this neurodegenerative disease. Nanosized particles have been proposed as suitable drug delivery systems to overcome BBB with the purpose of increasing bioavailability of drugs in the brain. Biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NPs) have been particularly regarded as promising drug delivery systems as they can be surface-tailored with functionalized molecules for site-specific targeting. In this review, a thorough discussion about the most recent functionalization strategies based on PLGA-NPs for AD and their mechanisms of action is provided, together with a description of AD pathogenesis and the role of the BBB in brain targeting. Keywords: functionalized PLGA nanoparticles; brain delivery; blood-brain barrier; Alzheimer's disease
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/177480
url https://hdl.handle.net/2445/177480
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/app11094305
Applied Sciences, 2021
https://doi.org/10.3390/app11094305
dc.rights.none.fl_str_mv cc-by (c) Del Amo Albiol, Laura et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Del Amo Albiol, Laura et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418636547981312
score 15.301603

Similares en LA Referencia